HER2+ Breast Cancer Targeted Therapy: Neoadjuvant Therapy and New Drugs

LAUR Repository

Show simple item record

dc.contributor.author Maadarani, Rola Jr
dc.date.accessioned 2021-06-24T06:41:35Z
dc.date.available 2021-06-24T06:41:35Z
dc.date.copyright 2021 en_US
dc.date.issued 2021-06-19
dc.identifier.uri http://hdl.handle.net/10725/12880
dc.description individual en_US
dc.description.abstract 5-20 % of breast cancer patients are diagnosed with overexpression of the HER2 (human epidermal receptor type 2) gene. This amplification is associated with an aggressive type of cancer, poor prognosis, and bad clinical outcomes. Neoadjuvant therapy is a standard treatment used to reduce the size of the tumor in HER2+ breast cancer and make it suitable for surgery. By down-regulating the tumor, neoadjuvant therapy was shown to effectively increase the pathologic complete response (pCR) and to reduce the scope of surgery. This paper reviews different types of drugs that are used as neoadjuvant agents for HER2+ targeted therapy. We will mention many clinical trials that led to the advancement in this treatment and will highlight different combinations between chemotherapy drugs and targeted HER2+ drugs to compare the efficiency and pCR of these combinations. Although chemotherapy plus HER2+ targeted therapy was shown as the most suitable neoadjuvant treatment, Metastatic breast cancer (MBC) is still a pending problem that is not solved by the previous treatments. For this purpose, we will also tackle the most recent drugs (tyrosine kinase inhibitor drugs, monoclonal antibody drugs, and antibody-drug conjugates) that are being tested for their efficiency on MBC. Although FDA-approved medications had improved the efficacy or reduced the side effects of HER2+ therapy in a particular way, neither of these therapies resulted in a major change in the industry and neither led to a final solution for MBC. en_US
dc.format Text en_US
dc.language.iso en en_US
dc.title HER2+ Breast Cancer Targeted Therapy: Neoadjuvant Therapy and New Drugs en_US
dc.type Capstones en_US
dc.term.submitted Spring en_US
dc.author.school SAS en_US
dc.author.idnumber 201704207 en_US
dc.author.department Natural Sciences en_US
dc.author.advisor Nasser, Rayan Jr
dc.keywords HER2 and Breast cancer en_US
dc.keywords PCR en_US
dc.keywords Neoadjuvant therapy en_US
dc.keywords Drugs en_US
dc.author.email rola.maadarani@lau.edu en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/thesis.php en_US
dc.rights.accessrights Public en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account